Share Price and Basic Stock Data
Last Updated: January 17, 2026, 7:21 am
| PEG Ratio | -3.01 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lasa Supergenerics Ltd operates within the chemicals sector, particularly focusing on specialty chemicals. The company’s recent market price stood at ₹9.38, with a market capitalization of ₹46.7 Cr. Over the past quarters, Lasa has exhibited fluctuating revenue performance. Sales reported in September 2022 were ₹33.66 Cr, which declined to ₹24.30 Cr by September 2023. The revenue trend showed some recovery, with sales reaching ₹39.39 Cr in September 2024 before dropping to ₹3.06 Cr in September 2025. This volatility indicates challenges in maintaining consistent sales growth. For the fiscal year ending March 2025, total sales were recorded at ₹142 Cr, compared to ₹130 Cr in March 2023, reflecting a slight increase. However, this growth is overshadowed by the overall declining trend in quarterly sales, indicating potential issues in market demand or operational efficiency.
Profitability and Efficiency Metrics
Profitability for Lasa Supergenerics has been under pressure, evidenced by a negative operating profit margin (OPM) of -130.72% as of September 2025. The company reported a net profit of -₹6.25 Cr for the same period, contributing to a trailing twelve months (TTM) net profit of -₹36 Cr. This negative profitability is a significant concern, especially when considering the P/E ratio of 97.3, which is considerably high relative to industry norms. The interest coverage ratio was recorded at 4.19x, suggesting that while the company can cover its interest obligations, its overall profitability remains weak. The return on equity (ROE) and return on capital employed (ROCE) both stood at approximately 1.01% and 1.00%, respectively, indicating inefficiencies in capital utilization. The company’s ability to manage costs effectively will be crucial for improving profitability.
Balance Sheet Strength and Financial Ratios
Lasa Supergenerics’ balance sheet reflects a concerning state of affairs, with total borrowings amounting to ₹7 Cr against reserves of only ₹6 Cr. This indicates a reliance on debt financing, which could pose risks if cash flow does not stabilize. The current ratio stood at a healthy 1.90, suggesting sufficient liquidity to meet short-term obligations. However, the quick ratio dropped to 0.46, indicating potential difficulties in covering liabilities without selling inventory. The book value per share has seen a decline, recorded at ₹16.71 in March 2025, down from ₹36.54 in March 2022. Additionally, the enterprise value (EV) of ₹83.63 Cr suggests that the market may be undervaluing the firm’s operational capabilities, given its recent performance. Overall, while liquidity ratios appear favorable, the company’s heavy reliance on debt and declining book value raises concerns about long-term financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lasa Supergenerics reveals a significant promoter stake of 53.65%, which has remained stable over recent quarters. This level of promoter ownership can signal confidence in the company’s long-term strategy. However, foreign institutional investors (FIIs) have shown no interest, holding 0% as of September 2025, which could reflect concerns regarding the company’s performance and profitability. Public shareholding comprised 46.35%, indicating a diverse investor base but also highlighting the absence of institutional backing. The total number of shareholders has increased slightly to 28,656, suggesting that retail interest remains. This increase, juxtaposed with a lack of institutional investment, may indicate a cautious outlook among larger investors regarding the company’s operational challenges and profitability issues.
Outlook, Risks, and Final Insight
The outlook for Lasa Supergenerics remains challenging due to persistent operational inefficiencies and declining profitability. Key risks include its high debt levels in relation to reserves and the lack of institutional investor confidence, which could limit future capital inflows. Additionally, the company’s fluctuating sales figures raise concerns about its ability to maintain stable revenue streams. On the positive side, the high promoter stake may provide a foundation for strategic decisions aimed at turnaround efforts. If Lasa can stabilize its sales and improve cost management, it may enhance profitability and investor confidence. Conversely, failure to address these operational challenges could lead to further declines in financial performance, impacting shareholder value and market perception.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 362 Cr. | 39.4 | 75.0/39.0 | 22.5 | 20.5 | 1.01 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 29.0 Cr. | 59.0 | 88.8/55.0 | 13.9 | 89.6 | 1.69 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.9 Cr. | 689 | 907/600 | 21.6 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,317 Cr. | 73.2 | 111/68.2 | 22.0 | 22.0 | 0.68 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 570 Cr. | 228 | 393/225 | 20.4 | 93.8 | 1.09 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,505.32 Cr | 673.05 | 62.12 | 182.97 | 0.46% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.66 | 31.70 | 35.32 | 30.56 | 24.30 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 |
| Expenses | 33.99 | 34.16 | 30.98 | 26.51 | 23.25 | 25.60 | 26.81 | 29.04 | 38.60 | 32.81 | 35.73 | 20.51 | 7.06 |
| Operating Profit | -0.33 | -2.46 | 4.34 | 4.05 | 1.05 | 1.06 | -3.99 | 1.80 | 0.79 | 0.27 | 3.41 | -0.50 | -4.00 |
| OPM % | -0.98% | -7.76% | 12.29% | 13.25% | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.50% | -130.72% |
| Other Income | -2.47 | 0.86 | -18.97 | 0.00 | 0.08 | 0.00 | -8.76 | 0.00 | 1.95 | 8.91 | -21.52 | -20.44 | 0.01 |
| Interest | 0.84 | 0.43 | 0.41 | 0.37 | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 |
| Depreciation | 3.09 | 3.09 | 4.17 | 2.65 | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.80 | 3.90 | 1.57 | 1.57 |
| Profit before tax | -6.73 | -5.12 | -19.21 | 1.03 | -2.11 | -2.06 | -15.97 | -1.86 | -1.31 | 5.91 | -22.12 | -22.54 | -5.68 |
| Tax % | -2.08% | -3.91% | -21.92% | 580.58% | -99.05% | -29.61% | -4.20% | 46.77% | 146.56% | 7.11% | -35.40% | -6.30% | 10.04% |
| Net Profit | -6.61 | -4.92 | -15.00 | -4.95 | -0.02 | -1.46 | -15.30 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 |
| EPS in Rs | -1.63 | -1.21 | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 | -1.25 |
Last Updated: December 30, 2025, 4:38 am
Below is a detailed analysis of the quarterly data for Lasa Supergenerics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 3.06 Cr.. The value appears to be declining and may need further review. It has decreased from 20.01 Cr. (Jun 2025) to 3.06 Cr., marking a decrease of 16.95 Cr..
- For Expenses, as of Sep 2025, the value is 7.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 20.51 Cr. (Jun 2025) to 7.06 Cr., marking a decrease of 13.45 Cr..
- For Operating Profit, as of Sep 2025, the value is -4.00 Cr.. The value appears to be declining and may need further review. It has decreased from -0.50 Cr. (Jun 2025) to -4.00 Cr., marking a decrease of 3.50 Cr..
- For OPM %, as of Sep 2025, the value is -130.72%. The value appears to be declining and may need further review. It has decreased from -2.50% (Jun 2025) to -130.72%, marking a decrease of 128.22%.
- For Other Income, as of Sep 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -20.44 Cr. (Jun 2025) to 0.01 Cr., marking an increase of 20.45 Cr..
- For Interest, as of Sep 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.03 Cr. (Jun 2025) to 0.12 Cr., marking an increase of 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 1.57 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.57 Cr..
- For Profit before tax, as of Sep 2025, the value is -5.68 Cr.. The value appears strong and on an upward trend. It has increased from -22.54 Cr. (Jun 2025) to -5.68 Cr., marking an increase of 16.86 Cr..
- For Tax %, as of Sep 2025, the value is 10.04%. The value appears to be increasing, which may not be favorable. It has increased from -6.30% (Jun 2025) to 10.04%, marking an increase of 16.34%.
- For Net Profit, as of Sep 2025, the value is -6.25 Cr.. The value appears strong and on an upward trend. It has increased from -21.12 Cr. (Jun 2025) to -6.25 Cr., marking an increase of 14.87 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.25. The value appears strong and on an upward trend. It has increased from -4.22 (Jun 2025) to -1.25, marking an increase of 2.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:03 am
| Metric | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 95 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 96 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -1 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | -1% | |
| Other Income | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -33 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 1 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 10 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -44 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -36 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -7.22 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -200.00% | 133.33% | 475.00% | -121.74% | -680.00% | 43.59% | 31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -700.00% | 333.33% | 341.67% | -596.74% | -558.26% | 723.59% | -11.77% |
Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 133% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -38% |
| 1 Year: | -73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:33 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Below is a detailed analysis of the balance sheet data for Lasa Supergenerics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 50.00 Cr..
- For Reserves, as of Sep 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 2.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing). It has decreased from 16.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
However, the Borrowings (7.00 Cr.) are higher than the Reserves (6.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -70.00 | -66.00 | -74.00 | -18.00 | 28.00 | -4.00 | -28.00 | -20.00 | 4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Diluted EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Cash EPS (Rs.) | -0.49 | -2.21 | -5.03 | 2.12 | 9.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 |
| Revenue From Operations / Share (Rs.) | 28.43 | 20.82 | 25.86 | 33.71 | 49.76 |
| PBDIT / Share (Rs.) | 2.25 | 0.45 | -0.95 | 3.86 | 11.62 |
| PBIT / Share (Rs.) | -0.20 | -1.68 | -3.63 | 0.41 | 7.73 |
| PBT / Share (Rs.) | -3.87 | -3.81 | -8.44 | -1.53 | 7.25 |
| Net Profit / Share (Rs.) | -2.94 | -4.34 | -7.71 | -1.32 | 5.60 |
| PBDIT Margin (%) | 7.91 | 2.17 | -3.69 | 11.44 | 23.36 |
| PBIT Margin (%) | -0.71 | -8.05 | -14.05 | 1.23 | 15.54 |
| PBT Margin (%) | -13.60 | -18.31 | -32.62 | -4.52 | 14.57 |
| Net Profit Margin (%) | -10.35 | -20.82 | -29.80 | -3.91 | 11.25 |
| Return on Networth / Equity (%) | -17.62 | -22.47 | -32.65 | -3.61 | 14.33 |
| Return on Capital Employeed (%) | -1.21 | -8.24 | -15.03 | 1.08 | 18.79 |
| Return On Assets (%) | -14.53 | -14.40 | -23.57 | -2.69 | 10.95 |
| Asset Turnover Ratio (%) | 1.13 | 0.66 | 0.71 | 0.67 | 0.92 |
| Current Ratio (X) | 1.90 | 0.77 | 0.91 | 1.65 | 1.59 |
| Quick Ratio (X) | 0.46 | 0.38 | 0.59 | 1.39 | 1.16 |
| Inventory Turnover Ratio (X) | 6.54 | 4.81 | 8.67 | 6.13 | 4.69 |
| Interest Coverage Ratio (X) | 4.19 | 1.17 | -1.15 | 389.33 | 24.08 |
| Interest Coverage Ratio (Post Tax) (X) | 1.34 | -5.71 | -3.50 | 62.86 | 12.60 |
| Enterprise Value (Cr.) | 83.63 | 108.58 | 90.15 | 152.41 | 239.23 |
| EV / Net Operating Revenue (X) | 0.58 | 1.04 | 0.69 | 1.11 | 1.18 |
| EV / EBITDA (X) | 7.42 | 47.93 | -18.82 | 9.71 | 5.06 |
| MarketCap / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| Price / BV (X) | 1.01 | 1.14 | 0.78 | 1.14 | 1.53 |
| Price / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| EarningsYield | -0.17 | -0.19 | -0.41 | -0.03 | 0.09 |
After reviewing the key financial ratios for Lasa Supergenerics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.49. This value is below the healthy minimum of 3. It has increased from -2.21 (Mar 24) to -0.49, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.43. It has increased from 20.82 (Mar 24) to 28.43, marking an increase of 7.61.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 2.25, marking an increase of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 0. It has increased from -1.68 (Mar 24) to -0.20, marking an increase of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.87. This value is below the healthy minimum of 0. It has decreased from -3.81 (Mar 24) to -3.87, marking a decrease of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 2. It has increased from -4.34 (Mar 24) to -2.94, marking an increase of 1.40.
- For PBDIT Margin (%), as of Mar 25, the value is 7.91. This value is below the healthy minimum of 10. It has increased from 2.17 (Mar 24) to 7.91, marking an increase of 5.74.
- For PBIT Margin (%), as of Mar 25, the value is -0.71. This value is below the healthy minimum of 10. It has increased from -8.05 (Mar 24) to -0.71, marking an increase of 7.34.
- For PBT Margin (%), as of Mar 25, the value is -13.60. This value is below the healthy minimum of 10. It has increased from -18.31 (Mar 24) to -13.60, marking an increase of 4.71.
- For Net Profit Margin (%), as of Mar 25, the value is -10.35. This value is below the healthy minimum of 5. It has increased from -20.82 (Mar 24) to -10.35, marking an increase of 10.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is -17.62. This value is below the healthy minimum of 15. It has increased from -22.47 (Mar 24) to -17.62, marking an increase of 4.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.21. This value is below the healthy minimum of 10. It has increased from -8.24 (Mar 24) to -1.21, marking an increase of 7.03.
- For Return On Assets (%), as of Mar 25, the value is -14.53. This value is below the healthy minimum of 5. It has decreased from -14.40 (Mar 24) to -14.53, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.13. It has increased from 0.66 (Mar 24) to 1.13, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 0.77 (Mar 24) to 1.90, marking an increase of 1.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.46, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.54. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 6.54, marking an increase of 1.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.19. This value is within the healthy range. It has increased from 1.17 (Mar 24) to 4.19, marking an increase of 3.02.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 3. It has increased from -5.71 (Mar 24) to 1.34, marking an increase of 7.05.
- For Enterprise Value (Cr.), as of Mar 25, the value is 83.63. It has decreased from 108.58 (Mar 24) to 83.63, marking a decrease of 24.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.58, marking a decrease of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 7.42. This value is within the healthy range. It has decreased from 47.93 (Mar 24) to 7.42, marking a decrease of 40.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For Price / BV (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.14 (Mar 24) to 1.01, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For EarningsYield, as of Mar 25, the value is -0.17. This value is below the healthy minimum of 5. It has increased from -0.19 (Mar 24) to -0.17, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
- Net Profit Margin: -10.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.21% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -17.62% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 96.4 (Industry average Stock P/E: 62.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.35%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Omkar Pravin Herlekar | Chairman & Managing Director |
| Mr. Prathamesh Chalke | Whole Time Director |
| Mr. Ketan Bhau Songal | Independent Director |
| Mr. Pravin Gadalya Lachake | Independent Director |
| Mr. Yogesh Hari Ughada | Independent Director |
| Mrs. Rekha Hemant Wakh | Independent Director |
FAQ
What is the intrinsic value of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd's intrinsic value (as of 18 January 2026) is ₹6.05 which is 34.52% lower the current market price of ₹9.24, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹46.3 Cr. market cap, FY2025-2026 high/low of ₹30.0/8.16, reserves of ₹6 Cr, and liabilities of ₹72 Cr.
What is the Market Cap of Lasa Supergenerics Ltd?
The Market Cap of Lasa Supergenerics Ltd is 46.3 Cr..
What is the current Stock Price of Lasa Supergenerics Ltd as on 18 January 2026?
The current stock price of Lasa Supergenerics Ltd as on 18 January 2026 is ₹9.24.
What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lasa Supergenerics Ltd stocks is ₹30.0/8.16.
What is the Stock P/E of Lasa Supergenerics Ltd?
The Stock P/E of Lasa Supergenerics Ltd is 96.4.
What is the Book Value of Lasa Supergenerics Ltd?
The Book Value of Lasa Supergenerics Ltd is 11.2.
What is the Dividend Yield of Lasa Supergenerics Ltd?
The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.
What is the ROCE of Lasa Supergenerics Ltd?
The ROCE of Lasa Supergenerics Ltd is 1.00 %.
What is the ROE of Lasa Supergenerics Ltd?
The ROE of Lasa Supergenerics Ltd is 1.01 %.
What is the Face Value of Lasa Supergenerics Ltd?
The Face Value of Lasa Supergenerics Ltd is 10.0.